A cancer cell-specific inducer of apoptosis

Human Gene Therapy

Volumn 18, Issue 6, 2007, Pages 547-561

  Green, Katie L ^a   Brown, Craig ^a   Roeder, Geraldine E ^a   Southgate, Thomas D ^b   Gaston, Kevin ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MUTANT PROTEIN; PROTEIN P53; VIRUS DNA; VIRUS PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CELL SPECIFICITY; CELL TYPE; CONTROLLED STUDY; HELA CELL; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; NONHUMAN; PROTEIN BINDING; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER; VIRUS CELL TRANSFORMATION; VIRUS GENOME; WART VIRUS;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CERCOPITHECUS AETHIOPS; COS CELLS; DNA-BINDING PROTEINS; FLOW CYTOMETRY; GENE TARGETING; GENE THERAPY; GENETIC VECTORS; HELA CELLS; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU NICK-END LABELING; KIDNEY; MICROSCOPY, FLUORESCENCE; NEOPLASMS; ONCOGENE PROTEINS, VIRAL; RECOMBINANT FUSION PROTEINS; TRANSFECTION; TREATMENT OUTCOME; VIRAL STRUCTURAL PROTEINS;

HUMAN HERPESVIRUS 1; HUMAN PAPILLOMAVIRUS;

EID: 34447117524     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2006.042     Document Type: Article

References (57)

1. BAKER, C.C., PHELPS, W.C., LINDGREN, V., BRAUN, M.J., GONDA, M.A., and HOWLEY, P.M. (1987). Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J. Virol. 61, 962-971.
2. BASTA, A., ADAMEK, K., and PITYNSKI, K. (1999). Intraepithelial neoplasia and early stage vulvar cancer: Epidemiological, clinical and virological observations. Eur. J. Gynaecol. Oncol. 20, 111-114.
3. BECKMANN, A.M., KIVIAT, N.B., DALING, J.R., SHERMAN, K.J., and McDOUGALL, J.K. (1988). Human papillomavirus type 16 in multifocal neoplasia of the female genital tract. Int. J. Gynecol. Pathol. 7, 39-47.
4. BIGLARI, A., SOUTHGATE, T.D., FAIRBAIRN, L.J., and GILHAM, D.E. (2006). Human monocytes expressing a CEA-specific chimeric CD64 receptor specifically target CEA expressing tumour cells in vitro and in vivo. Gene Ther. 13, 602-610.
5. BRAY, F., LOOS, A.H., McCARRON, P., WEIDERPASS, E., ARBYN, M., MOLLER, H., HAKAMA, M, and PARKIN, D.M. (2005). Trends in cervical squamous cell carcinoma incidence in 13 European countries: Changing risk and the effects of screening. Cancer Epidemiol. Biomarkers Prev. 14, 677-686.
6. COLEMAN, M.P., RACHET, B., WOODS, L.M., MITRY, E., RIGA, M., COOPER, N., QUINN, M.J., BRENNER, H., and ESTEVE, J. (2004). Trends and socioeconomic inequalities in cancer survival in England and Wales up to 2001. Br. J. Cancer 90, 1367-1373.
7. CORDEN, S.A., SANT-CASSIA, L.J., EASTON, A.J., and MORRIS, A.G. (1999). The integration of HPV-18 DNA in cervical carcinoma. Mol. Pathol. 52, 275-282.
8. DELL, G., and GASTON, K. (2001). Human papillomaviruses and their role in cervical cancer. Cell. Mol. Life Sci. 58, 1923-1942.
9. DELVENNE, P., HUBERT, P., JACOBS, N., GIANNINI, S.L., HAVARD, L., RENARD, I., SABOULARD, D., and BONIVER, J. (2001). The organotypic culture of HPV-transformed keratinocytes: An effective in vitro model for the development of new immunotherapeutic approaches for mucosal (pre)neoplastic lesions. Vaccine 19, 2557-2564.
10. DESAINTES, C., DEMERET, C., GOYAT, S., YANIV, M., and THIERRY, F. (1997). Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis. EMBO J. 16, 504-514.
11. DESAINTES, C., GOYAT, S., GARBAY, S., YANIV, M., and THIERRY, F. (1999). Papillomavirus E2 induces p53-independent apoptosis in HeLa cells. Oncogene 18, 4538-4545.
12. DOWHANICK, J.J., MCBRIDE, A.A., and HOWLEY, P.M. (1995). Suppression of cellular proliferation by the papillomavirus E2 protein. J. Virol. 69, 7791-7799.
13. DREYER, G. (2005). Operative management of cervical cancer. Best Pract. Res. Clin. Obstet. Gynaecol. 19, 563-576.
14. DURST, M., KLEINHEINZ, A., HOTZ, M., and GISSMAN, L. (1985). The physical state of human papillomavirus type 16 DNA in benign and malignant genital tumours. J. Gen. Virol. 66, 1515-1522.
15. DYSON, N., HOWLEY, P.M., MUNGER, K., and HARLOW, E. (1989). The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243, 934-937.
16. ELLIOTT, G., and O'HARE, P. (1999). Intercellular trafficking of VP22-GFP fusion proteins. Gene Ther. 6, 149-151.
17. FRANCIS, D.A., SCHMID, S.I., and HOWLEY, P.M. (2000). Repression of the integrated papillomavirus E6/E7 promoter is required for growth suppression of cervical cancer cells. J. Virol. 74, 2679-2686.
18. FRATTINI, M.G., HURST, S.D., LIM, H.B., SWAMINATHAN, S., and LAIMINS, L.A. (1997). Abrogation of a mitotic checkpoint by E2 proteins from oncogenic human papillomaviruses correlates with increased turnover of the p53 tumor suppressor protein. EMBO J. 16, 318-331.
19. GOODWIN, E.C., and DIMAIO, D. (2000). Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. Proc. Natl. Acad. Sci. U.S.A. 97, 12513-12518.
20. GOODWIN, E.C., NAEGER, L.K., BREIDING, D.E., ANDROPHY, E.J., and DIMAIO, D. (1998). Transactivation-competent bovine papillomavirus E2 protein is specifically required for efficient repression of human papillomavirus oncogene expression and for acute growth inhibition of cervical carcinoma cell lines. J. Virol. 72, 3925-3934.
21. GREEN, K.L., and GASTON, K. (2006). Development of a topical protein therapeutic for human papillomavirus and associated cancers. BioDrugs 20, 209-218.
22. GREEN, K.L., SOUTHGATE, T.D., MULRYAN, K., FAIRBAIRN, L.J., STERN, P.L., and GASTON, K. (2006). Diffusible VP22-E2 protein kills bystander cells and offers a route for cervical cancer gene therapy. Hum. Gene Ther. 17, 147-157.
23. HUBERT, P., VAN DEN BRULE, F., GIANNINI, S.L., FRANZEN-DETROOZ, E., BONIVER, J., and DELVENNE, P. (1999). Colonization of in vitro-formed cervical human papillomavirus-associated (pre)neoplastic lesions with dendritic cells: Role of granulocyte/macrophage colony stimulating factor. Am. J. Pathol. 154, 775-784.
24. HWANG, E.S., RIESE, D.J., SETTLEMAN, J., NILSON, L.A., HONIG, J., FLYNN, S., and DIMAIO, D. (1993). Inhibition of cervical carcinoma cell line proliferation by the introduction of a bovine papillomavirus regulatory gene. J. Virol. 67, 3720-3729.
25. HWANG, E.S., NAEGER, L.K., and DIMAIO, D. (1996). Activation of the endogenous p53 growth inhibitory pathway in HeLa cervical carcinoma cells by expression of the bovine papillomavirus E2 gene. Oncogene 12, 795-803.
26. JONES, D.L., THOMPSON, D.A., and MUNGER, K. (1997). Destabilization of the RB tumor suppressor protein and stabilization of p53 contribute to HPV type 16 E7-induced apoptosis. Virology 239, 97-107.
27. KALANTARI, M., KARLSEN, F., KRISTENSEN, G., HOLM, R., HAGMAR, B., and JOHANSSON, B. (1998). Disruption of the E1 and E2 reading frames of HPV 16 in cervical carcinoma is associated with poor prognosis. Int. J. Gynecol. Pathol. 17, 146-153.
28. KITCHENER, H. (2002). Evidence-based medicine applied to cervical cancer. Virus Res. 89, 175-181.
29. KOWALCZYK, A.M., ROEDER, G.E., GREEN, K., STEVENS, D.J., and GASTON, K. (2005). Measuring the induction or inhibition of apoptosis by HPV proteins. In Human Papilloma Viruses: Methods and Protocols. J. Doorbar and C. Davy, eds. (Humana Press, Totowa, NJ).
30. KUSAMA, K., JIANG, Y., TOGUCHI, M., OHNO, J., SHIKATA, H., SAKASHITA, H., and SAKAGAMI, H. (2000). Use of the monoclonal antibody M30 for detecting HSG cell apoptosis. Anticancer Res. 20, 151-154.
31. LUNDBERG, M., and JOHANSSON, M. (2001). Is VP22 nuclear homing an artifact? Nat. Biotechnol. 19, 713-714.
32. MASSIMI, P., PIM, D., BERTOLI, C., BOUVARD, V., and BANKS, L. (1999). Interaction between the HPV-16 E2 transcriptional activator and p53. Oncogene 18, 7748-7754.
33. MIETZ, J.A., UNGER, T., HUIBREGTSE, J.M., and HOWLEY, P.M. (1992). The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J. 11, 5013-5020.
34. MUNGER, K., PHELPS, W.C., BUBB, V., HOWLEY, P.M., and SCHLEGEL, R. (1989a). The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol. 63, 4417-4421.
35. MUNGER, K., WERNESS, B.A., DYSON, N., PHELPS, W.C., HARLOW, E., and HOWLEY, P.M. (1989b). Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 8, 4099-4105.
36. MUNGER, K., YEE, C.L., PHELPS, W.C., PIETENPOL, J.A., MOSES, H.L., and HOWLEY, P.M. (1991). Biochemical and biological differences between E7 oncoproteins of the high- and low-risk human papillomavirus types are determined by amino-terminal sequences. J. Virol. 65, 3943-3948.
37. NISHIMURA, A., ONO, T., ISHIMOTO, A., DOWHANICK, J.J., FRIZZELL, M.A., HOWLEY, P.M., and SAKAI, H. (2000). Mechanisms of human papillomavirus E2-mediated repression of viral oncogene expression and cervical cancer cell growth inhibition. J. Virol. 74, 3752-3760.
38. PARISH, J., KOWALCZYK, A.M., CHEN, H., ROEDER, G.E., SESSIONS, R., BUCKLE, M., and GASTON, K. (2006). The E2 proteins from high- and low-risk HPV types differ in their ability to bind p53 and induce apoptotic cell death. J. Virol. 80, 4580-4590.
39. PARKIN, D.M., BRAY, F., FERLAY, J., and PISANI, P. (2005). Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108.
40. PFISTER, H. (1992). Human papillomaviruses and skin cancer. Semin. Cancer Biol. 3, 263-271.
41. PHELAN, A., ELLIOTT, G., and O'HARE, P. (1998). Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat. Biotechnol. 16, 440-443.
42. ROEDER, G.E., PARISH, J.L., STERN, P.L., and GASTON, K. (2004). Herpes simplex virus VP22-human papillomavirus E2 fusion proteins produced in mammalian or bacterial cells enter mammalian cells and induce apoptotic cell death. Biotechnol. Appl. Biochem. 40, 157-165.
43. ROMANCZUK, H., and HOWLEY, P.M. (1992). Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity. Proc. Natl. Acad. Sci. U.S.A. 89, 3159-3163.
44. RUTJES, S.A., BOSMA, P.J., ROHN, J.L., NOTEBORN, M.H., and WESSELING, J.G. (2003). Induction of insolubility by herpes simplex virus VP22 precludes intercellular trafficking of N-terminal apoptin-VP22 fusion proteins. J. Mol. Med. 81, 558-565.
45. SANCHEZ-PEREZ, A.M., SORIANO, S., CLARKE, A.R., and GASTON, K. (1997). Disruption of the human papillomavirus type 16 E2 gene protects cervical carcinoma cells from E2F-induced apoptosis. J. Gen. Virol. 78, 3009-3018.
46. SCHEFFNER, M., WERNESS, B.A., HUIBREGTSE, J.M., LEVINE, A.J., and HOWLEY, P.M. (1990). The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63, 1129-1136.
47. SCHWARTZ, S.M., DALING, J.R., DOODY, D.R., WIPF, G.C., CARTER, J.J., MADELEINE, M.M., MAO, E.J., FITZGIBBONS, E.D., HUANG, S., BECKMANN, A.M., MCDOUGALL, J.K., and GALLOWAY, D.A. (1998). Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J. Natl. Cancer Inst. 90, 1626-1636.
48. SCHWARZ, E., FREESE, U.K., GISSMANN, L., MAYER, W., ROGGENBUCK, B., STREMLAU, A., and ZUR HAUSEN, H. (1985). Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 314, 111-114.
49. STERN, P.L. (2005). Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination. J. Clin. Virol. 32(Suppl. 1), S72-S81.
50. STOREY, A., PICCINI, A., MASSIMI, P., BOUVARD, V., and BANKS, L. (1995). Mutations in the human papillomavirus type 16 E2 protein identify a region of the protein involved in binding to E1 protein. J. Gen. Virol. 76, 819-826.
51. STROH, C., HELD, J., SAMRAJ, A.K., and SCHULZE-OSTHOFF, K. (2003). Specific inhibition of transcription factor NF-κB through intracellular protein delivery of IκBα by the herpes virus protein VP22. Oncogene 22, 5367-5373.
52. THAIN, A., WEBSTER, K., EMERY, D., CLARKE, A.R., and GASTON, K. (1997). DNA binding and bending by the human papillomavirus type 16 E2 protein: Recognition of an extended binding site. J. Biol. Chem. 272, 8236-8242.
53. VOUSDEN, K.H. (2002). Activation of the p53 tumor suppressor protein. Biochim. Biophys. Acta 1602, 47-59.
54. WALBOOMERS, J.M., JACOBS, M.V., MANOS, M.M., BOSCH, F.X., KUMMER, J.A., SHAH, K.V., SNIJDERS, P.J., PETO, J., MEIJER, C.J., and MUNOZ, N. (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189, 12-19.
55. WEBSTER, K., PARISH, J., PANDYA, M., STERN, P.L., CLARKE, A.R., and GASTON, K. (2000). The human papillomavirus (HPV) 16 E2 protein induces apoptosis in the absence of other HPV proteins and via a p53-dependent pathway. J. Biol. Chem. 275, 87-94.
56. YANG, B.H., BRAY, F.I., PARKIN, D.M., SELLORS, J.W., and ZHANG, Z.F. (2004). Cervical cancer as a priority for prevention in different world regions: An evaluation using years of life lost. Int. J. Cancer 109, 418-424.
57. YEE, C., KRISHNAN-HEWLETT, I., BAKER, C.C., SCHLEGEL, R., and HOWLEY, P.M. (1985). Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines. Am. J. Pathol. 119, 361-366.